| abstract |
Disclosed herein are nitrogen containing heteroaryl compounds of general formula (I), wherein the substituents are as defined within the specification, processes for their preparation, compositions comprising said compounds and uses thereof. Said compounds are useful in the treatment or prophylaxis of psychotic disorders, schizophrenia, positive, negative and/or cognitive symptoms associated with schizophrenia, delusional disorder, substance-induced psychotic disorder, anxiety disorders, panic disorder, obsessive/compulsive disorders, acute stress disorder, generalized anxiety disorder, drug addictions, movement disorders, Parkinson's disease, restless leg syndrome, cognition deficiency disorders, Alzheimer's disease, multi-infarct dementia, mood disorders, depression, bipolar disorders, neuropsychiatric conditions, psychosis, attention-deficitihyperactivity disorder, attentional disorders, diabetes and related disorders, type 2 diabetes mellitus, neurodegenerative disorders, Huntington's disease, multiple sclerosis, stroke, spinal cord injury, solid tumors, hematological malignancies, renal cell carcinoma or breast cancer. Particularly preferred compounds include: 6-Cyclopropyl-N-(4-cyclopropylcarbamoyl-pyridin-3-yl)-3-(pyrimidin-5-ylamino)-pyridine-2-carboximidic acid, 6-Cyclopropyl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (2,3-difluoro-6-methylcarbamoyl-phenyl)-amide, 3-(Pyrimidin-5-ylamino)-6-(tetrahydro-furan-3-yl)-pyrazine-2-carboxylic acid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 2-Isopropyl-5-(pyrimidin-5-ylamino)-pyrimidine-4-carboxylic acid (1-methyl-3-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 6-Morpholin-4-yl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (1-methyl-5-methylcarbamoyl-1H-pyrazol-4-yl)-amide, 6-Azetidin-1-yl-3-(pyrimidin-5-ylamino)-pyrazine-2-carboxylic acid (1-methyl-5-methylcarbamoyl-lH-pyrazol-4-yl)-amide. |